A full GMP process to select and amplify epitope-specific T lymphocytes for adoptive immunotherapy of metastatic melanoma

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Labarriere, N ^a,b,c   Fortun, A ^a,b,c   Bellec, A ^d   Khammari, A ^a,b,c,d   Dreno, B ^a,b,c,d   Saiagh S ^d   Lang, F ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CNRS   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; MELAN A; PEPTIDE; EPITOPE;

ADOPTIVE IMMUNOTHERAPY; CELL EXPANSION; CELL SELECTION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEEDER CELL; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; METASTATIC MELANOMA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ARTICLE; CHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MELANOMA; METASTASIS; METHODOLOGY; PATHOLOGY; STANDARD; TUMOR CELL LINE;

CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MART-1 ANTIGEN; MELANOMA; NEOPLASM METASTASIS; PEPTIDES; T-LYMPHOCYTES;

EID: 84886667225     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/932318     Document Type: Review

References (28)

1. Rooney C. M., Roskrow M. A., Suzuki N., Ng C. Y. C., Brenner M. K., Heslop H., Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Annals of Oncology 1998 9 5 S129 S132 2-s2.0-0032448280 (Pubitemid 29049132)
2. Dréno B., Nguyen J.-M., Khammari A., Pandolfino M., Tessier M., Bercegeay S., Cassidanius A., Lemarre P., Billaudel S., Labarrière N., Jotereau F., Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunology, Immunotherapy 2002 51 10 539 546 2-s2.0-0036034859 10.1007/s00262-002-0315-1 (Pubitemid 35232003)
3. Khammari A., Nguyen J.-M., Pandolfino M. C., Quereux G., Brocard A., Bercegeay S., Cassidanius A., Lemarre P., Volteau C., Labarrière N., Jotereau F., Dréno B., Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunology, Immunotherapy 2007 56 11 1853 1860 2-s2.0-34548158425 10.1007/s00262-007-0340-1 (Pubitemid 47313089)
4. Labarrière N., Pandolfino M.-C., Gervois N., Khammari A., Tessier M.-H., Dréno B., Jotereau F., Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunology, Immunotherapy 2002 51 10 532 538 2-s2.0-0036032173 10.1007/s00262-002-0313-3 (Pubitemid 35232002)
5. Khammari A., Labarrière N., Vignard V., Nguyen J.-M., Pandolfino M.-C., Knol A. C., Quéreux G., Saiagh S., Brocard A., Jotereau F., Dreno B., Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. The Journal of Investigative Dermatology 2009 129 12 2835 2842 2-s2.0-79959351392
6. Vignard V., Lemercier B., Lim A., Pandolfino M.-C., Guilloux Y., Khammari A., Rabu C., Echasserieau K., Lang F., Gougeon M.-L., Dreno B., Jotereau F., Labarriere N., Adoptive transfer of tumor-reactive melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional melan-A-specific T cells. Journal of Immunology 2005 175 7 4797 4805 2-s2.0-25444494125 (Pubitemid 41362023)
7. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proceedings of the National Academy of Sciences of the United States of America 2002 99 25 16168 16173 2-s2.0-0037058993 10.1073/pnas.242600099 (Pubitemid 35462767)
8. Barrow C., Browning J., MacGregor D., Davis I. D., Sturrock S., Jungbluth A. A., Cebon J., Tumor antigen expression in melanoma varies according to antigen and stage. Clinical Cancer Research 2006 12 3 764 771 2-s2.0-32944457941 10.1158/1078-0432.CCR-05-1544 (Pubitemid 43259856)
9. Godet Y., Moreau-Aubry A., Guilloux Y., Vignard V., Khammari A., Dreno B., Jotereau F., Labarriere N., MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. Journal of Experimental Medicine 2008 205 11 2673 2682 2-s2.0-58149153043 10.1084/jem.20081356
10. Coulie P. G., Brichard V., Van Pel A., Wölfel T., Schneider J., Traversari C., Mattei S., De Plaen E., Lurquin C., Szikora J.-P., Renauld J.-C., Boon T., A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. Journal of Experimental Medicine 1994 180 1 35 42 2-s2.0-0028303166 10.1084/jem.180.1.35 (Pubitemid 24181053)
11. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Sakaguchi K., Appella E., Yannelli J. R., Adema G. J., Miki T., Rosenberg S. A., Identification of a human melanoma antigen recognized by tumor- infiltrating lymphocytes associated with in vivo tumor rejection. Proceedings of the National Academy of Sciences of the United States of America 1994 91 14 6458 6462 2-s2.0-0028298174 10.1073/pnas.91.14.6458 (Pubitemid 24200680)
12. Godet Y., Desfrançois J., Vignard V., Schadendorf D., Khammari A., Dreno B., Jotereau F., Labarrière N., Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy. European Journal of Immunology 2010 40 6 1786 1794 2-s2.0-77953308650 10.1002/eji.200940132
13. Pittet M. J., Zippelius A., Valmori D., Speiser D. E., Cerottini J.-C., Romero P., Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends in Immunology 2002 23 7 325 328 2-s2.0-0036644737 10.1016/S1471-4906(02)02244-5 (Pubitemid 34717898)
14. Zippelius A., Pittet M. J., Batard P., Rufer N., De Smedt M., Guillaume P., Ellefsen K., Valmori D., Liénard D., Plum J., Robson MacDonald H., Speiser D. E., Cerottini J.-C., Romero P., Thymic selection generates a large T cell pool recognizing a self-peptide in humans. Journal of Experimental Medicine 2002 195 4 485 494 2-s2.0-0037128179 10.1084/jem.20011658 (Pubitemid 34461301)
15. Benlalam H., Vignard V., Khammari A., Bonnin A., Godet Y., Pandolfino M.-C., Jotereau F., Dreno B., Labarrière N., Infusion of Melan-A/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunology, Immunotherapy 2007 56 4 515 526 2-s2.0-33846850619 10.1007/s00262-006-0204-0 (Pubitemid 46204537)
16. Bouquié R., Bonnin A., Bernardeau K., Khammari A., Dréno B., Jotereau F., Labarrière N., Lang F., A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes. Cancer Immunology, Immunotherapy 2009 58 4 553 566 2-s2.0-59449102958 10.1007/s00262-008-0578-2
17. Labarrière N., Gervois N., Bonnin A., Bouquié R., Jotereau F., Lang F., PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting. Cancer Immunology, Immunotherapy 2008 57 2 185 195 2-s2.0-36349013166 10.1007/s00262-007-0361-9 (Pubitemid 350159920)
18. Bodinier M., Peyrat M.-A., Tournay C., Davodeau F., Romagne F., Bonneville M., Lang F., Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nature Medicine 2000 6 6 707 710 2-s2.0-0034047716 10.1038/76292 (Pubitemid 30398798)
19. Valmori D., Fonteneau J.-F., Lizana C. M., Gervois N., Liénard D., Rimoldi D., Jongeneel V., Jotereau F., Cerottini J.-C., Romero P., Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. Journal of Immunology 1998 160 4 1750 1758 2-s2.0-0032520084 (Pubitemid 28110836)
20. Gervois N., Labarriere N., Le Guiner S., Pandolfino M.-C., Fonteneau J.-F., Guilloux Y., Diez E., Dreno B., Jotereau F., High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells. Clinical Cancer Research 2000 6 4 1459 1467 2-s2.0-0034006540 (Pubitemid 30226235)
21. Richter G. H. S., Mollweide A., Hanewinkel K., Zobywalski C., Burdach S., CD25 blockade protects T cells from activation-induced cell death (AICD) via maintenance of TOSO expression. Scandinavian Journal of Immunology 2009 70 3 206 215 2-s2.0-69149094287 10.1111/j.1365-3083.2009.02281.x
22. Decot V., Voillard L., Latger-Cannard V., Aissi-Rothé L., Perrier P., Stoltz J. F., Bensoussan D., Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression. Experimental Hematology 2010 38 5 351 362 2-s2.0-77951499495 10.1016/j.exphem.2010.02.006
23. Goldstein J. D., Perol L., Zaragoza B., Baeyens A., Marodon G., Piaggio E., Role of cytokines in thymus- versus peripherally derived-regulatory T cell differentiation and function. Frontiers in Immunology 2013 4 article 155
24. + T cells for the treatment of patients with metastatic melanoma. Journal of Clinical Oncology 2006 24 31 5060 5069 2-s2.0-33750940238 10.1200/JCO.2006.07.1100 (Pubitemid 46631410)
25. Meidenbauer N., Marienhagen J., Laumer M., Vogl S., Heymann J., Andreesen R., Mackensen A., Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. Journal of Immunology 2003 170 4 2161 2169 2-s2.0-0037442228 (Pubitemid 36197440)
26. Palermo B., Campanelli R., Garbelli S., Mantovani S., Della Cuna G. R., Necker A., Manganoni A. M., Carella G., Rivoltini L., Lantelme E., Giachino C., Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis. Melanoma Research 2002 12 5 491 498 2-s2.0-0036752157 10.1097/00008390-200209000-00011 (Pubitemid 35264726)
27. Filipazzi P., Pilla L., Mariani L., Patuzzo R., Castelli C., Camisaschi C., Maurichi A., Cova A., Rigamonti G., Giardino F., Di Florio A., Asioli M., Frati P., Sovena G., Squarcina P., Maio M., Danielli R., Chiarion-Sileni V., Villa A., Lombardo C., Tragni G., Santinami M., Parmiani G., Rivoltini L., Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clinical Cancer Research 2012 18 6485 6496
28. Valmori D., Lévy F., Miconnet I., Zajac P., Spagnoli G. C., Rimoldi D., Liénard D., Cerundolo V., Cerottini J.-C., Romero P., Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue. Journal of Immunology 2000 164 2 1125 1131 2-s2.0-17544403916 (Pubitemid 30043743)